Commercial Drugmakers & Pipeline Renewal

Established drug franchises offer a demand driver distinct from AI infrastructure spending and financing conditions. The technology drawdown makes a diversified basket of commercial drugmakers worth considering, while approaching earnings can clarify franchise durability and pipeline investment. Patent expirations, clinical setbacks and pricing pressure remain material risks, so this is not a blanket defensive trade. Launch basket (equal weight): ABBV, AMGN, LLY, MRK, MRNA, GILD Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.